| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Harvard Bioscience (NASDAQ:HBIO) sees Q4 sales of $22.500 million-$24.500 million vs $23.100 million analyst estimate.
Harvard Bioscience (NASDAQ:HBIO) reported quarterly sales of $20.591 million which beat the analyst consensus estimate of $20.0...
- SEC Filing